Väitös (syöpäbiologia): MPhil Kwan Long Mung
Aika
31.3.2023 klo 12.00 - 16.00
MPhil Kwan Long Mung esittää väitöskirjansa “Genomic editing to elucidate the effects of PIM kinases on cancer cell signalling” julkisesti tarkastettavaksi Turun yliopistossa perjantaina 31.3.2023 klo 12:00 (Turun yliopisto, päärakennus, Säästöpankki-sali, Turku).
Yleisön on mahdollista seurata väitöstä etäyhteyden kautta: https://utu.zoom.us/j/65639832521 (kopioi linkki selaimeen).
Vastaväittäjänä toimii tohtori Kathy Gately (Trinity College Dublin, Irlanti) ja kustoksena dosentti Päivi J. Koskinen (Turun yliopisto). Tilaisuus on englanninkielinen. Väitöksen alana on syöpäbiologia.
Väitöskirja yliopiston julkaisuarkistossa: https://www.utupub.fi/handle/10024/174345 (kopioi linkki selaimeen).
***
Tiivistelmä väitöstutkimuksesta:
Cancer is a disease in which cells grow and divide uncontrollably. PIM kinases are proteins that are found in various types of cancer cells and they control networks of signaling pathways that are essential for tumorigenesis and development. Because they help cancer cells to survive, grow, and spread to other parts of the body, pharmacological inhibitors that target PIM kinases are being developed, and some of them are currently in clinical trials.
With the use of state-of-art CRISPR genome editing technology, this dissertation research identifies three new targets of PIM kinases: CP actin capping proteins, LKB1 tumor suppressor, and LDHA metabolic enzyme. The study highlights the versatile roles of PIM kinases in regulating cell motility, proliferation, and metabolism and emphasizes the importance of co-targeting PIM kinases with other proteins or cellular pathways in cancer therapy.
Yleisön on mahdollista seurata väitöstä etäyhteyden kautta: https://utu.zoom.us/j/65639832521 (kopioi linkki selaimeen).
Vastaväittäjänä toimii tohtori Kathy Gately (Trinity College Dublin, Irlanti) ja kustoksena dosentti Päivi J. Koskinen (Turun yliopisto). Tilaisuus on englanninkielinen. Väitöksen alana on syöpäbiologia.
Väitöskirja yliopiston julkaisuarkistossa: https://www.utupub.fi/handle/10024/174345 (kopioi linkki selaimeen).
***
Tiivistelmä väitöstutkimuksesta:
Cancer is a disease in which cells grow and divide uncontrollably. PIM kinases are proteins that are found in various types of cancer cells and they control networks of signaling pathways that are essential for tumorigenesis and development. Because they help cancer cells to survive, grow, and spread to other parts of the body, pharmacological inhibitors that target PIM kinases are being developed, and some of them are currently in clinical trials.
With the use of state-of-art CRISPR genome editing technology, this dissertation research identifies three new targets of PIM kinases: CP actin capping proteins, LKB1 tumor suppressor, and LDHA metabolic enzyme. The study highlights the versatile roles of PIM kinases in regulating cell motility, proliferation, and metabolism and emphasizes the importance of co-targeting PIM kinases with other proteins or cellular pathways in cancer therapy.